SOPHiA GENETICS CSO tax-related sale of 33 shares

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale.

Rhea-AI Filing Summary

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert reported a small tax-related share sale. On March 18, 2026, he sold 33 Ordinary Shares at an average price of $4.76 per share and continued to hold 92,386 shares afterward.

The company states this was a “sell to cover” transaction executed in the open market solely to satisfy tax obligations tied to vesting restricted stock units, and it did not represent a discretionary trade.

Insider Trade Summary

Net Seller: 33 shares

Net Sell 1 txn

Insider Puylaert Kevin

Role Chief Sales Officer

Sold 33 shs ($157.08)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	33	$4.76	$157.08

Holdings After Transaction: Ordinary Shares — 92,386 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SOPHiA GENETICS (SOPH) report for Kevin Puylaert?

SOPHiA GENETICS reported that Chief Sales Officer Kevin Puylaert sold 33 Ordinary Shares. The sale was linked to tax obligations arising from restricted stock unit vesting and was structured as a non-discretionary “sell to cover” transaction in the open market.

How many SOPHiA GENETICS (SOPH) shares did Kevin Puylaert sell and at what price?

Kevin Puylaert sold 33 Ordinary Shares of SOPHiA GENETICS at an average price of $4.76 per share. This was a relatively small transaction executed to cover tax obligations tied to vesting equity awards, rather than a discretionary portfolio decision.

How many SOPHiA GENETICS (SOPH) shares does Kevin Puylaert hold after this Form 4 transaction?

Following the reported transaction, Kevin Puylaert holds 92,386 Ordinary Shares of SOPHiA GENETICS directly. This indicates the 33 shares sold for tax purposes represent only a very small portion of his overall reported shareholding in the company.

Was the SOPHiA GENETICS (SOPH) insider sale by Kevin Puylaert discretionary?

The sale was not discretionary. The company states the 33 shares were sold as a “sell to cover” transaction to satisfy tax obligations upon vesting of restricted stock units, meaning the sale was mechanically triggered by tax needs, not active trading decisions.

What does a “sell to cover” transaction mean for SOPHiA GENETICS (SOPH) insiders?

A “sell to cover” transaction means an insider sells a limited number of shares to pay taxes due when equity awards vest. For SOPHiA GENETICS, Kevin Puylaert’s 33-share sale was described as sell-to-cover, emphasizing a tax-driven, non-discretionary disposition rather than a strategic share sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Puylaert Kevin

(Last) (First) (Middle)

C/O SOPHIA GENETICS SA

LA PIECE 12

(Street)

ROLLE 1180

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Sales Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/19/2026		S		33(1)	D	$4.76	92,386	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold by the Reporting Person in the open market to satisfy tax obligations in connection with the vesting of restricted stock units on March 18, 2026. The sales were effected as a "sell to cover" transaction and do not represent discretionary trades.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Kevin Puylaert	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)